Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

688000 Y-27632 - CAS 331752-47-7 - Calbiochem

688000
Purchase on Sigma-Aldrich

Aperçu

Replacement Information

Tableau de caractéristiques principal

CAS #Empirical Formula
331752-47-7C₁₄H₂₁N₃O · 2HCl · H₂O

Products

RéférenceConditionnement Qté
688000-100MG Ampoule plast. 100 mg
688000-10MG Flacon en verre 10 mg
688000-1MG Ampoule plast. 1 mg
688000-5MG Flacon en verre 5 mg
Description
OverviewA highly potent, cell-permeable, reversible, and selective inhibitor of Rho-associated protein kinases (Ki = 140 nM for p160ROCK). Also inhibits ROCK-II with equal potency. The inhibition is competitive with respect to ATP. Exhibits 10- to 50-fold lower affinity for PKCε than p160ROCK. Does not affect the activity of p21-activated protein kinase (PAK) even at higher concentrations (~100 µM). Also acts as a potent inhibitor of agonist-induced Ca2+ sensitization of myosin phosphorylation and smooth muscle contraction. Prevents apoptosis and enhances the survival and cloning efficiency of dissociated hES cells without affecting their pluripotency. Pretreatment with Y-27632 reduces the risk of lung injury in rat models of sepsis. A 5 mM (500 µg/296 µl) solution of Y-27632 (Cat. No. 688001) in H2O and a 10 mM solution in DMSO (Cat. No. 688002) are also available.
Catalogue Number688000
Brand Family Calbiochem®
Synonyms(R)-(+)-trans-N-(4-Pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide, 2HCl, ROCK Inhibitor, Rho Kinase Inhibitor VI
References
ReferencesCinel, I., et al. 2012. J. Thorac . Dis. 4, 30.
Watanabe, K., et al. 2007. Nature Biotech. 25, 681.
Chitaley, K., et al. 2001. Nat. Med. 7, 119.
Davies, S.P., et al. 2000. Biochem. J. 351, 95.
Narumiya, S., et al. 2000. Methods Enzymol. 325, 273.
Hirose, M., et al. 1998. J. Cell Biol. 141, 1625.
Maekawa, M., et al. 1999. Science 285, 895.
Uehata, M., et al. 1997. Nature 389, 990.
Product Information
CAS number331752-47-7
ATP CompetitiveY
DeclarationSold under license of PCT Application W098/06,433A1 and under license from Mitsubishi Pharma Tanabe Corporation.
FormWhite solid
Hill FormulaC₁₄H₂₁N₃O · 2HCl · H₂O
Chemical formulaC₁₄H₂₁N₃O · 2HCl · H₂O
Hygroscopic Hygroscopic
ReversibleY
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
ApplicationY-27632, CAS 146986-50-7, is a cell-permeable, reversible, inhibitor of Rho kinases (Ki = 140 nM for p160ROCK). Enhances survival & cloning efficiency of ESC without affecting their pluripotency.
Biological Information
Primary Targetp160 Rho-associated protein kinases (ROCK)
Primary Target K<sub>i</sub>140 nM for p160 Rho-associated protein kinases (ROCK)
Purity≥95% by HPLC
Physicochemical Information
Cell permeableY
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
R PhraseR: 20/21/22

Harmful by inhalation, in contact with skin and if swallowed.
S PhraseS: 36

Wear suitable protective clothing.
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Harmful
Storage -20°C
Protect from Light Protect from light
Hygroscopic Hygroscopic
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for 6 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Référence GTIN
688000-100MG 04055977225402
688000-10MG 04055977225396
688000-1MG 07790788052362
688000-5MG 07790788052379

Documentation

Y-27632 - CAS 331752-47-7 - Calbiochem FDS

Titre

Fiche de données de sécurité des matériaux (FDS) 

Y-27632 - CAS 331752-47-7 - Calbiochem Certificats d'analyse

TitreNuméro de lot
688000

Références bibliographiques

Aperçu de la référence bibliographique
Cinel, I., et al. 2012. J. Thorac . Dis. 4, 30.
Watanabe, K., et al. 2007. Nature Biotech. 25, 681.
Chitaley, K., et al. 2001. Nat. Med. 7, 119.
Davies, S.P., et al. 2000. Biochem. J. 351, 95.
Narumiya, S., et al. 2000. Methods Enzymol. 325, 273.
Hirose, M., et al. 1998. J. Cell Biol. 141, 1625.
Maekawa, M., et al. 1999. Science 285, 895.
Uehata, M., et al. 1997. Nature 389, 990.

Brochure

Titre
Bulk Product Guide

Fiche technique

Titre
Reprogramming Cell Fate and Function Novel Strategies for iPSC Generation, Characterization, and Differentiation

Citations

Titre
  • Cinel, I., et al. 2012. J. Thorac . Dis. 4, 30.
  • Jennifer L. Farmer, et al. (2008) Galectin 15 (LGALS15) functions in trophectoderm migration and attachment. Federation of American Societies for Experimental Biology Journal 22, 548-560.
  • James J. Fiordalisi, Patricia J. Keller and Adrienne D. Cox. (2006) PRL Tyrosine Phosphatases Regulate Rho Family GTPases to Promote Invasion and Motility. Cancer Research 66, 3153-3161.
  • Karen E. Porter, et al. (2004) Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Cardiovascular Research 61, 745-755.
  • Rick B. Vega, et al. (2004) Protein Kinases C and D Mediate Agonist-Dependent Cardiac Hypertrophy through Nuclear Export of Histone Deacetylase 5. Molecular and Cellular Biology 24, 8374-8385.
  • Fiche technique

    Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

    Revision27-February-2012 RFH
    Synonyms(R)-(+)-trans-N-(4-Pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide, 2HCl, ROCK Inhibitor, Rho Kinase Inhibitor VI
    DescriptionA highly potent, cell-permeable, reversible, and selective inhibitor of Rho-associated protein kinase (Ki = 140 nM for p160ROCK (ROCK-I). Also inhibits ROCK-II with almost equal potency. Inhibition is achieved by competing with ATP for binding to the catalytic site. Exhibits 10- to 50-fold lower affinity for PKCε than p160ROCK. Does not affect the activity of p21-activated protein kinase (PAK) even at high concentrations (~100 µM). Also acts as a potent inhibitor of agonist-induced Ca2+ sensitization of myosin phosphorylation and smooth muscle contractions (IC50 = 700 nM for phenylephrine-induced contractions in aortic strips). Prevents apoptosis and enhances the survival and cloning efficiency of dissociated hES cells without affecting their pluripotency. Pretreatment with Y-27632 reduces the risk of lung injury in rat models of sepsis.
    FormWhite solid
    Intert gas (Yes/No) Packaged under inert gas
    CAS number331752-47-7
    Chemical formulaC₁₄H₂₁N₃O · 2HCl · H₂O
    Structure formulaStructure formula
    Purity≥95% by HPLC
    SolubilityH₂O (100 mg/ml)
    Storage Protect from light
    -20°C
    Hygroscopic
    Do Not Freeze Ok to freeze
    Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for 6 months at -20°C.
    Toxicity Harmful
    ReferencesCinel, I., et al. 2012. J. Thorac . Dis. 4, 30.
    Watanabe, K., et al. 2007. Nature Biotech. 25, 681.
    Chitaley, K., et al. 2001. Nat. Med. 7, 119.
    Davies, S.P., et al. 2000. Biochem. J. 351, 95.
    Narumiya, S., et al. 2000. Methods Enzymol. 325, 273.
    Hirose, M., et al. 1998. J. Cell Biol. 141, 1625.
    Maekawa, M., et al. 1999. Science 285, 895.
    Uehata, M., et al. 1997. Nature 389, 990.
    Citation
  • Cinel, I., et al. 2012. J. Thorac . Dis. 4, 30.
  • Jennifer L. Farmer, et al. (2008) Galectin 15 (LGALS15) functions in trophectoderm migration and attachment. Federation of American Societies for Experimental Biology Journal 22, 548-560.
  • James J. Fiordalisi, Patricia J. Keller and Adrienne D. Cox. (2006) PRL Tyrosine Phosphatases Regulate Rho Family GTPases to Promote Invasion and Motility. Cancer Research 66, 3153-3161.
  • Karen E. Porter, et al. (2004) Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Cardiovascular Research 61, 745-755.
  • Rick B. Vega, et al. (2004) Protein Kinases C and D Mediate Agonist-Dependent Cardiac Hypertrophy through Nuclear Export of Histone Deacetylase 5. Molecular and Cellular Biology 24, 8374-8385.